COMBINED THERAPY Photodynamic Therapy and Bevacizumab to Treat Myopic Neovascular Membranes. One-Year Follow-Up

被引:8
作者
Carmen Desco, M. [1 ]
Mataix, Jorge [1 ]
Garcia-Pous, Maria [1 ]
Palacios-Pozo, Elena [1 ]
Navea, Amparo [1 ]
机构
[1] FOM, E-46015 Valencia, Spain
来源
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES | 2011年 / 31卷 / 03期
关键词
combined therapy; photodynamic therapy; bevacizumab; choroidal neovascularization; myopia; SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; INTRAVITREAL TRIAMCINOLONE INJECTION; PATHOLOGICAL MYOPIA; SECONDARY; RANIBIZUMAB; AVASTIN;
D O I
10.1097/IAE.0b013e3181f201a6
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose: The purpose of this study was to evaluate whether combined customized photodynamic therapy (PDT) and bevacizumab in myopic choroidal neovascularization can improve vision and whether it is possible to decrease the frequency and number of intravitreal antiangiogenic injections. Methods: A prospective, consecutive, noncomparative, interventional case series of 36 patients with myopic choroidal neovascularization, treated with an initial dose of PDT and intravitreal bevacizumab 48 hours to 60 hours afterward. Retreatments were carried out as required with monthly bevacizumab and PDT every 3 months if there were relapses. Follow-up lasted 1 year in all cases. Results: The mean best-corrected visual acuity increased from 44 letters before the initial treatment to 59.5 letters at the 12-month follow-up (P < 0.01). Compared with initial vision, 94.5% of the eyes had the same or better vision and 5.5% lost fewer than 6 lines of vision. The mean number of PDT treatments was 1.1 per patient, and the mean number of bevacizumab injections was 1.5 per patient. Only 1 initial treatment with PDT + bevacizumab was necessary in 28 cases (77.8%). Conclusion: Combined personalized PDT + bevacizumab therapy makes it possible to obtain visual results similar to those obtained in monotherapy studies but with fewer intravitreal injections. It appears to be an interesting option for this type of patient. RETINA 31: 475-481, 2011
引用
收藏
页码:475 / 481
页数:7
相关论文
共 34 条
[1]  
Arnold J, 2001, OPHTHALMOLOGY, V108, P841
[2]  
AVILA MP, 1984, OPHTHALMOLOGY, V91, P1573
[3]   Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal [J].
Benjamin, LE ;
Golijanin, D ;
Itin, A ;
Pode, D ;
Keshet, E .
JOURNAL OF CLINICAL INVESTIGATION, 1999, 103 (02) :159-165
[4]   Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia - 2-year results of a randomized clinical Trial - VIP report no. 3 [J].
Blinder, KJ ;
Blumenkranz, MS ;
Bressler, NM ;
Bressler, SB ;
Donati, G ;
Lewis, H ;
Lim, JI ;
Menchini, U ;
Miller, JW ;
Mones, JM ;
Potter, MJ ;
Pournaras, C ;
Reaves, A ;
Rosenfeld, P ;
Schachat, AP ;
Schmidt-Erfurth, U ;
Sickenberg, M ;
Singerman, LJ ;
Slakter, J ;
Strong, HA ;
Virgili, G ;
Williams, GA .
OPHTHALMOLOGY, 2003, 110 (04) :667-673
[5]  
Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
[6]   Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularisation: 1-year results of a prospective pilot study [J].
Chan, W-M ;
Lai, T. Y. Y. ;
Liu, D. T. L. ;
Lam, D. S. C. .
BRITISH JOURNAL OF OPHTHALMOLOGY, 2009, 93 (02) :150-154
[7]   Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularization - Six-month results of a prospective pilot study [J].
Chan, Wai-Man ;
Lai, Timothy Y. Y. ;
Liu, David T. L. ;
Lam, Dennis S. C. .
OPHTHALMOLOGY, 2007, 114 (12) :2190-2196
[8]  
Chan WM, 2007, BRIT J OPHTHALMOL, V91, P174, DOI 10.1136/bjo.2006.103606
[9]   Choroidal neovascularisation in pathological myopia: an update in management [J].
Chan, WM ;
Ohji, M ;
Lai, TYY ;
Liu, DTL ;
Tano, Y ;
Lam, DSC .
BRITISH JOURNAL OF OPHTHALMOLOGY, 2005, 89 (11) :1522-1528
[10]   The biology of VEGF and its receptors [J].
Ferrara, N ;
Gerber, HP ;
LeCouter, J .
NATURE MEDICINE, 2003, 9 (06) :669-676